Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of VLS-101 in Patients With Solid Tumors

NCT04504916 is registered in ClinicalTrials.gov with VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.

NCT NCT04504916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Lead sponsor
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase
Phase 2
Overall status
Terminated
Start date
October 7, 2020
Completion date
June 12, 2023
Enrollment
102 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

er-negative breast cancer, er-positive breast cancer, estrogen-receptor-negative breast cancer, estrogen-receptor-positive breast cancer, gastric cancer, her2-negative breast cancer, non-squamous non-small-cell lung cancer, nsclc, pancreatic cancer, platinum-resistant ovarian cancer, pr-negative breast cancer, pr-positive breast cancer, progesterone-receptor negative breast cancer, progesterone-receptor-positive breast cancer, triple-negative breast cancer